The distinction between drug vs medical device has historically seemed clear:
- a drug acts through a pharmacological, immunological, or metabolic mechanism;
- a medical device acts primarily through a physical or mechanical mode of action.
Yet today’s therapeutic innovation is blurring this separation.
Combination products, medical software, devices incorporating medicinal substances, and digital therapeutics are all making the drug vs medical device distinction more complex. As a result, it is no longer only a legal or scientific question—it has become a strategic regulatory issue.
Drug vs Medical Device: Legally Distinct Definitions… in Theory
The drug
In France, the legal definition of a medicinal product is based on Article L.5111-1 of the French Public Health Code.
European evaluation is coordinated by the European Medicines Agency:
https://www.ema.europa.eu/en/human-regulatory-overview
Clinical trials are governed by Regulation (EU) 536/2014:
https://eur-lex.europa.eu/eli/reg/2014/536/oj
In France, the competent authority is the ANSM:
https://ansm.sante.fr
The medical device
The European regulatory framework for medical devices is defined by Regulation (EU) 2017/745 (MDR):
https://eur-lex.europa.eu/eli/reg/2017/745/oj
European Commission explanatory guide:
https://health.ec.europa.eu/medical-devices-sector_en
Medical devices must demonstrate performance and safety through continuous clinical evaluation.
In theory, the drug vs medical device distinction therefore remains well established. In practice, however, innovation increasingly challenges this framework.
Combination Products: The Core of the Complexity
The MDR includes specific provisions for devices incorporating a medicinal substance with an ancillary action (Article 1(8) MDR).
In such cases:
- the notified body assesses the device,
- the EMA may be consulted regarding the substance,
- the qualification depends on the product’s principal mode of action.
However, determining that principal mode of action can be difficult.
And this is precisely where the drug vs medical device distinction becomes strategic.
The qualification selected has a direct impact on:
- clinical design
- timelines
- development costs
- market access strategy
For innovative hybrid products, drug vs medical device is often one of the earliest and most critical regulatory questions.
Medical software and rule 11 as a Major Turning Point
Medical software, especially Software as a Medical Device (SaMD), is a strong illustration of how the drug vs medical device boundary is evolving.
Rule 11 of the MDR has reclassified many software solutions into class IIa or higher.
Guide MDCG on software classification.
An algorithm supporting prescribing decisions may qualify as a medical device.
But if that same algorithm directly influences the administration of a medicinal product, the drug vs medical device analysis becomes even more strategic.
This means that for connected technologies and digital health tools, drug vs medical device is not a theoretical debate. It determines the applicable regulatory route, the level of evidence required, and the overall development strategy.
Real-World Data and Converging Evidence Requirements
The regulatory frameworks for drugs and medical devices are gradually converging:
- stronger clinical data requirements for medical devices
- growing integration of real-world data for medicines
The underlying logic is becoming similar:
✔ continuous demonstration of value
✔ active post-market surveillance
✔ greater transparency
This evolution reinforces the importance of the drug vs medical device distinction, because both categories now rely on increasingly demanding evidence-generation models.
The difference is no longer simply about the nature of the product, but about how evidence must be generated, maintained, and defended over time.
A Strategic Issue, Not Just a Regulatory One
The choice of qualification influences:
- the evaluation procedure
- the level of clinical evidence required
- time-to-market
- reimbursement strategy
For medicinal products, this includes interaction with the French National Authority for Health:
https://www.has-sante.fr
For medical devices, reimbursement listing and pricing will also depend on the strength of the evidence generated.
A poor assessment of drug vs medical device qualification can therefore lead to major delays, additional costs, and regulatory setbacks.
Anticipating Drug vs Medical Device Qualification Early in Innovation
In a context where the boundaries between drug vs medical device are becoming more complex, regulatory qualification can no longer be treated at the end of development.
An early analysis helps to:
- identify the main competent authority (EMA or notified body under MDR),
- anticipate the expected level of clinical evidence,
- structure the evidence-generation strategy,
- avoid late reclassifications, which are often particularly costly.
The European Commission has also established consultation mechanisms in case of uncertainty regarding product qualification.
Official guidance on qualification and classification of devices:
For its part, the European Medicines Agency offers scientific advice procedures that help anticipate regulatory expectations:
https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance
Anticipating these interactions not only secures the regulatory pathway but also helps optimize time-to-market.
In an environment where therapeutic innovation is increasingly hybrid—combining active substances, devices, and sometimes algorithms—the drug vs medical device question must be integrated into the strategic design of the product from the outset.
Conclusion: Drug vs Medical Device, a Regulatory Distinction That Has Become Strategic
Drug vs medical device remains a legally valid distinction.
However, therapeutic innovation is creating an expanding grey zone in which regulatory qualification becomes a decisive strategic choice.
In this context, the drug vs medical device analysis can no longer be treated as a downstream regulatory formality.
It must be incorporated from the earliest stages of product design.
